| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.032 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |